Global Zoster Vaccine Market

Zoster Vaccine Comprehensive Study by Type (Live Vaccines, Attenuated Vaccines), Application (Herpes Zoster, Others), End Users (Hospitals, Clinic, Others) Players and Region - Global Market Outlook to 2026

Zoster Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Zoster Vaccine Market Overview:
Herpes zoster is defined as the viral infection which affects the cranial nerves that originate in the brain. It mostly causes a blistering painful rash on the skin that lasts for more than 2 weeks. It is mainly produced by the varicella-zoster virus, the same virus which also causes chicken pox. This virus can stay latent for so many years in the human body. Consequently, anyone who has had chickenpox in the past is at the risk of developing shingles. On December 2018, as per an article published by Disease Control and Prevention (CDC), more than 1 million cases shingles reported every year in the United States. Hence, the rising number of viral infectious diseases worldwide and rising old population worldwide are some of the major drivers which are propelling the growth of the market.

Growth Drivers
  • Increase in the Prevalence and Incidence of Shingles Disease around the World
  • Increase in the Global Ageing Population

Roadblocks
  • High Cost of Zoster Vaccines

Opportunities
  • Rising Demand from Emerging Economics Such as India, China and Others

Challenges
  • Lack of Awareness and Unfavorable Insurance Coverage


Competitive Landscape:

Some of the key players profiled in the report are Merck& Co., Inc. (United States), GlaxoSmithKline plc (United Kingdom), Cipla Inc. (India) and Pfizer Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Zoster Vaccine market by 2026. Considering Market by End Users, the sub-segment i.e. Hospitals will boost the Zoster Vaccine market.

On October 2016, the GlaxoSmithKline (United States) Company had received FDA approval for its shingles vaccine. This approval will help in strengthening the position of the company in the United States. and On 2006, the Merck & Co., Inc. (United States) Company had licensed Zostavax for prevention of shingles. This will, in turn, propel the growth of Zoster vaccine market.

What Can be Explored with the Zoster Vaccine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Zoster Vaccine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Zoster Vaccine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Zoster Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Zoster Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Raw Material Suppliers, Manufacturers, System Integrators, Distributors and End-users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Live Vaccines
  • Attenuated Vaccines
By Application
  • Herpes Zoster
  • Others
By End Users
  • Hospitals
  • Clinic
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence and Incidence of Shingles Disease around the World
      • 3.2.2. Increase in the Global Ageing Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness and Unfavorable Insurance Coverage
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement of the Zoster Vaccine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Zoster Vaccine, by Type, Application, End Users and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Zoster Vaccine (Value)
      • 5.2.1. Global Zoster Vaccine by: Type (Value)
        • 5.2.1.1. Live Vaccines
        • 5.2.1.2. Attenuated Vaccines
      • 5.2.2. Global Zoster Vaccine by: Application (Value)
        • 5.2.2.1. Herpes Zoster
        • 5.2.2.2. Others
      • 5.2.3. Global Zoster Vaccine by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinic
        • 5.2.3.3. Others
      • 5.2.4. Global Zoster Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Zoster Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck& Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cipla Inc. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Zoster Vaccine Sale, by Type, Application, End Users and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Zoster Vaccine (Value)
      • 7.2.1. Global Zoster Vaccine by: Type (Value)
        • 7.2.1.1. Live Vaccines
        • 7.2.1.2. Attenuated Vaccines
      • 7.2.2. Global Zoster Vaccine by: Application (Value)
        • 7.2.2.1. Herpes Zoster
        • 7.2.2.2. Others
      • 7.2.3. Global Zoster Vaccine by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinic
        • 7.2.3.3. Others
      • 7.2.4. Global Zoster Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Zoster Vaccine: by Type(USD Million)
  • Table 2. Zoster Vaccine Live Vaccines , by Region USD Million (2015-2020)
  • Table 3. Zoster Vaccine Attenuated Vaccines , by Region USD Million (2015-2020)
  • Table 4. Zoster Vaccine: by Application(USD Million)
  • Table 5. Zoster Vaccine Herpes Zoster , by Region USD Million (2015-2020)
  • Table 6. Zoster Vaccine Others , by Region USD Million (2015-2020)
  • Table 7. Zoster Vaccine: by End Users(USD Million)
  • Table 8. Zoster Vaccine Hospitals , by Region USD Million (2015-2020)
  • Table 9. Zoster Vaccine Clinic , by Region USD Million (2015-2020)
  • Table 10. Zoster Vaccine Others , by Region USD Million (2015-2020)
  • Table 11. South America Zoster Vaccine, by Country USD Million (2015-2020)
  • Table 12. South America Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 13. South America Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 14. South America Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 15. Brazil Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 16. Brazil Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 17. Brazil Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 18. Argentina Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 19. Argentina Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 20. Argentina Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 21. Rest of South America Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 24. Asia Pacific Zoster Vaccine, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 28. China Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 29. China Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 30. China Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 31. Japan Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 32. Japan Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 33. Japan Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 34. India Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 35. India Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 36. India Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 37. South Korea Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 38. South Korea Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 39. South Korea Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 40. Taiwan Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 41. Taiwan Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 42. Taiwan Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 43. Australia Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 44. Australia Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 45. Australia Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 49. Europe Zoster Vaccine, by Country USD Million (2015-2020)
  • Table 50. Europe Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 51. Europe Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 52. Europe Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 53. Germany Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 54. Germany Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 55. Germany Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 56. France Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 57. France Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 58. France Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 59. Italy Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 60. Italy Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 61. Italy Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 62. United Kingdom Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 65. Netherlands Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 66. Netherlands Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 67. Netherlands Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 68. Rest of Europe Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 71. MEA Zoster Vaccine, by Country USD Million (2015-2020)
  • Table 72. MEA Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 73. MEA Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 74. MEA Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 75. Middle East Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 76. Middle East Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 77. Middle East Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 78. Africa Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 79. Africa Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 80. Africa Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 81. North America Zoster Vaccine, by Country USD Million (2015-2020)
  • Table 82. North America Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 83. North America Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 84. North America Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 85. United States Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 86. United States Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 87. United States Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 88. Canada Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 89. Canada Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 90. Canada Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 91. Mexico Zoster Vaccine, by Type USD Million (2015-2020)
  • Table 92. Mexico Zoster Vaccine, by Application USD Million (2015-2020)
  • Table 93. Mexico Zoster Vaccine, by End Users USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Zoster Vaccine: by Type(USD Million)
  • Table 99. Zoster Vaccine Live Vaccines , by Region USD Million (2021-2026)
  • Table 100. Zoster Vaccine Attenuated Vaccines , by Region USD Million (2021-2026)
  • Table 101. Zoster Vaccine: by Application(USD Million)
  • Table 102. Zoster Vaccine Herpes Zoster , by Region USD Million (2021-2026)
  • Table 103. Zoster Vaccine Others , by Region USD Million (2021-2026)
  • Table 104. Zoster Vaccine: by End Users(USD Million)
  • Table 105. Zoster Vaccine Hospitals , by Region USD Million (2021-2026)
  • Table 106. Zoster Vaccine Clinic , by Region USD Million (2021-2026)
  • Table 107. Zoster Vaccine Others , by Region USD Million (2021-2026)
  • Table 108. South America Zoster Vaccine, by Country USD Million (2021-2026)
  • Table 109. South America Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 110. South America Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 111. South America Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 112. Brazil Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 113. Brazil Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 114. Brazil Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 115. Argentina Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 116. Argentina Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 117. Argentina Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 118. Rest of South America Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 119. Rest of South America Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 120. Rest of South America Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 121. Asia Pacific Zoster Vaccine, by Country USD Million (2021-2026)
  • Table 122. Asia Pacific Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 123. Asia Pacific Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 124. Asia Pacific Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 125. China Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 126. China Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 127. China Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 128. Japan Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 129. Japan Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 130. Japan Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 131. India Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 132. India Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 133. India Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 134. South Korea Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 135. South Korea Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 136. South Korea Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 137. Taiwan Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 138. Taiwan Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 139. Taiwan Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 140. Australia Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 141. Australia Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 142. Australia Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 143. Rest of Asia-Pacific Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 144. Rest of Asia-Pacific Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 145. Rest of Asia-Pacific Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 146. Europe Zoster Vaccine, by Country USD Million (2021-2026)
  • Table 147. Europe Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 148. Europe Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 149. Europe Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 150. Germany Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 151. Germany Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 152. Germany Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 153. France Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 154. France Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 155. France Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 156. Italy Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 157. Italy Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 158. Italy Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 159. United Kingdom Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 160. United Kingdom Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 161. United Kingdom Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 162. Netherlands Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 163. Netherlands Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 164. Netherlands Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 165. Rest of Europe Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 166. Rest of Europe Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 167. Rest of Europe Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 168. MEA Zoster Vaccine, by Country USD Million (2021-2026)
  • Table 169. MEA Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 170. MEA Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 171. MEA Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 172. Middle East Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 173. Middle East Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 174. Middle East Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 175. Africa Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 176. Africa Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 177. Africa Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 178. North America Zoster Vaccine, by Country USD Million (2021-2026)
  • Table 179. North America Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 180. North America Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 181. North America Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 182. United States Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 183. United States Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 184. United States Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 185. Canada Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 186. Canada Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 187. Canada Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 188. Mexico Zoster Vaccine, by Type USD Million (2021-2026)
  • Table 189. Mexico Zoster Vaccine, by Application USD Million (2021-2026)
  • Table 190. Mexico Zoster Vaccine, by End Users USD Million (2021-2026)
  • Table 191. Research Programs/Design for This Report
  • Table 192. Key Data Information from Secondary Sources
  • Table 193. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Zoster Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Zoster Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Zoster Vaccine: by End Users USD Million (2015-2020)
  • Figure 7. South America Zoster Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Zoster Vaccine Share (%), by Country
  • Figure 9. Europe Zoster Vaccine Share (%), by Country
  • Figure 10. MEA Zoster Vaccine Share (%), by Country
  • Figure 11. North America Zoster Vaccine Share (%), by Country
  • Figure 12. Global Zoster Vaccine share by Players 2020 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Merck& Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 15. Merck& Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 16. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 19. Cipla Inc. (India) Revenue: by Geography 2020
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Global Zoster Vaccine: by Type USD Million (2021-2026)
  • Figure 23. Global Zoster Vaccine: by Application USD Million (2021-2026)
  • Figure 24. Global Zoster Vaccine: by End Users USD Million (2021-2026)
  • Figure 25. South America Zoster Vaccine Share (%), by Country
  • Figure 26. Asia Pacific Zoster Vaccine Share (%), by Country
  • Figure 27. Europe Zoster Vaccine Share (%), by Country
  • Figure 28. MEA Zoster Vaccine Share (%), by Country
  • Figure 29. North America Zoster Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck& Co., Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Cipla Inc. (India)
  • Pfizer Inc. (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 249 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Zoster Vaccine Market Quantitative research analysis
Global Zoster Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Zoster Vaccine market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Zoster Vaccine market are Merck& Co., Inc. (United States), GlaxoSmithKline plc (United Kingdom), Cipla Inc. (India) and Pfizer Inc. (United States), to name a few.
"Technology Advancement of the Zoster Vaccine" is seen as one of major influencing trends for Zoster Vaccine Market during projected period 2020-2026.

Know More About Global Zoster Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Corticosteroids Comprehensive Study by Type (Glucocorticoids, Mineralocorticoids), Application (Hospital, Clinic, Others), Route of Administration (Oral, Intravenous, Topical/Enema), Form (Capsules, ...
$ 3350
Chlorhexidine Gluconate Comprehensive Study by Type (CHG 2% Solution, CHG 4% Solution, CHG 20% Solution, CHG 0.12% Solution, Others), Application (Skin Preparation, Surgical Preparation, Pharmaceutic...
$ 3750
Rosemary Extract Comprehensive Study by Type (Carnosic acid, Rosemarinic acid, Essential oil, Others), Application (Food industry (Sauces, Dressings, and Condiments, Bakery and Confectionery, Dairy P...
$ 3750
ePharmacy - Comprehensive Study by Type (Skin Care, Dental, Cold and Flu, Vitamins, Weight Loss, Others), Drug Type (Prescription Drugs, Over The Counter (OTC) Drugs) Players and Region - Global Mark...
$ 3500
Capillary Blood Collection Tubes Comprehensive Study by Type (Plastic Blood Collection Tubes, Glass Blood Collection Tubes, Stainless Steel Blood Collection Tubes, Ceramic Blood Collection Tubes), Ap...
$ 3800
Porcine Vaccines Comprehensive Study by Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), Application (Swine Fever Vaccin...
$ 3450